Harry Hixson has retired from his position as CEO of Sequenom, effective beginning at the company's annual meeting in June. He will continue to serve as chairman of the company's board of directors. William Welch, currently president and COO will assume the role of CEO upon his retirement. Welch joined the company in 2011 as senior vice president of diagnostics.
Dirk van den Boom, who currently serves as the company's executive vice president of research and development and CTO, will be promoted to chief scientific and chief strategy officer at the annual meeting.
In addition, CFO Paul Maier will also retire at the annual meeting. Carolyn Beaver, currently vice president and chief accounting officer will assume the role of CFO.
The American Association for Cancer Research will award Levi Garraway the Jane Cooke Wright lectureship at its annual meeting in April. The award was established in 2006 to recognize a scientist who has made important contributions to the field of cancer research and furthered the advancement of minority investigators in cancer research.
Garraway is an associate professor of medicine in the department of medical oncology at the Dana-Farber Cancer Institute.
Saskia Biskup, cofounder and managing director of CeGaT, has won the European Commission's 2014 EU Prize for Women Innovators. Biskup cofounded the genetic diagnostics company CeGaT in 2009. It offers a range of tests, including next-gen sequencing-based panels for inherited disorders.
The American Society of Clinical Oncology has named Daniel Von Hoff one of ASCO's 50 oncology luminaries. Von Hoff is physician-in-chief and a distinguished professor at the Translational Genomics Research Institute and CSO for Scottsdale Healthcare's Virginia G. Piper Cancer Center Clinical Trials.